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Yu-xian Pan,1 Wei Hao,1 Ya-bo Mei,1 Vincent C. C. Cheng,2
and Kwok-yung Yuen2
1Zhujiang Hospital, Southern Medical University, Guangzhou, and 2Department
of Microbiology, The University of Hong Kong, Hong Kong Special
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Cross-reactivity between antibodies to different human co-
ronaviruses (HCoVs) has not been systematically studied. By
use of Western blot analysis, indirect immunofluorescence
assay (IFA), and enzyme-linked immunosorbent assay (ELISA),
antigenic cross-reactivity between severe acute respiratory
syndrome (SARS)–associated coronavirus (SARS-CoV) and 2
HCoVs (229E and OC43) was demonstrated in immunized
animals and human serum. In 5 of 11 and 10 of 11 patients
with SARS, paired serum samples showed a4-fold increase
in antibody titers against HCoV-229E and HCoV-OC43, re-
spectively, by IFA. Overall, serum samples from convalescent
patients who had SARS had a 1-way cross-reactivity with the
2 known HCoVs. Antigens of SARS-CoV and HCoV-OC43
were more cross-reactive than were those of SARS-CoV and
HCoV-229E.
Severe acute respiratory syndrome (SARS) is an emerging in-
fectious disease caused by a novel coronavirus (CoV) designated
“SARS-associated CoV” (SARS-CoV) [1]. Three known anti-
genic groups of CoVs are associated with diseases in animals
and humans [2]. The known human CoVs (HCoVs)—HCoV-
229E, in CoV group 1, and HCoV-OC43, in CoV group 2—
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are generally recognized to cause mild upper respiratory tract
diseases and, rarely, lower respiratory tract diseases [2]. Phy-
logenetic analyses show that SARS-CoV is not closely related
to any of the previously characterized CoVs [3]. However, some
investigators, using SARS-CoV–infected Vero cells in immu-
nohistochemical antibody tests, have observed cross-reactions
between SARS-CoV and group I CoVs, but seroepidemiological
studies revealed that there were no cross-reactions with SARS-
CoV–infected Vero cells in 13 and 14 paired serum samples
from patients with HCoV-OC43 and HCoV-229E, respectively
[1]. Serum samples from group I CoV–infected animals also
cross-reacted with the recombinant nucleocapsid protein of
SARS-CoV [4]. Results of the recombinant nucleocapsid pro-
tein–based ELISA were positive in 1.04% of serum samples
from healthy blood donors [5]. The nature of this antigenic
cross-reactivity is still unknown. In the present study, we cloned
the nucleocapsid genes of SARS-CoV, HCoV-229E, and HCoV-
OC43 and produced specific animal antisera to determine if
the nucleocapsid protein is responsible for the observed anti-
genic cross-reactivity. In addition, the antigenic relationships
among SARS-CoV, HCoV-229E, and HCoV-OC43 were further
studied using serum samples from healthy donors and patients
with SARS.
Subjects, materials, and methods. HCoV strains 229E (ATCC
VR740) and OC43 (ATCC VR759) were maintained in normal
human fetal lung fibroblast cells (MRC-5; ATCC CCL-171) and
African green monkey kidney cells (BSC-1; ATCC CCL-26) in
MEM (Gibco BRL) supplemented with 10% fetal bovine serum
(Gibco BRL). A SARS-CoV (HKU-39849) strain isolated from
a patient with SARS in Hong Kong was inoculated into Vero
E6 cells as described elsewhere [6, 7]. All experiments with live
viruses were performed in a biosafety level 3 laboratory.
Murine monoclonal antibodies specific for the nucleocapsid
proteins of HCoV-229E and HCoV-OC43 were obtained from
a commercial source (Chemicon International). A murine mono-
clonal antibody specific for the nucleocapsid protein of SARS-
CoV was produced in our laboratory [8]. Antiserum to whole
virus was prepared in female New Zealand White rabbits as
described elsewhere [9].
The cDNA fragments of the nucleocapsid protein of the 3
CoVs were cloned into the prokaryotic expression vector pQE30
(Qiagen) in frame and upstream of the 6 histidine (His6) resi-
due series, and the His6-tagged nucleocapsid proteins were ex-
pressed and purified using an Ni-NTA affinity column (Qiagen)
in accordance with the manufacturer’s instructions. The ex-
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Table 1. Antibody responses to human coronavirus (HCoV)–229E, HCoV-OC43, and severe acute respiratory syndrome (SARS)–as-
sociated CoV (SARS-CoV) in 11 paired serum samples from patients with SARS.
Patient Age/sex
Days
after onset
of symptoms
SARS-CoV
IgM (ELISA)
SARS-CoV
IgG (ELISA)
Antibody titer ratio
in CoV-infected cell lines by IFAa
Antibody titer ratio to CoV
nucleocapsid proteins by ELISAb
SARS-CoV HCoV-229E HCoV-OC43 SARS-CoV HCoV-229E HCoV-OC43
1 39/F 4   8 1 4 4.2 0.5 0.5
38 + +
2 19/F 5   16 1 4 26 2.1 1
69 + +
3 27/F 1   16 1 8 50 2.5 1.1
24 + +
4 19/F 5 +  16 2 4 41 18 0.7
19 + +
5 40/F 7   4 2 8 19 0.9 0.8
21 + +
6 41/F 3   16 2 2 72 1.7 0.9
25 + +
7 32/M 6 +  4 4 4 12 15 1.2
12 + +
8 26/F 4   16 8 8 75 1.7 1.3
15 + +
9 33/M 1   16 4 4 5.2 1.0 1.3
37 + +
10 56/F 5   16 8 4 5.2 0.6 0.9
159 + +
11 20/F 7   8 8 8 13 2.6 0.6
14 + +
NOTE. IFA, immunofluorescence assay.
a The IFA antibody titer ratio was determined in serum samples in a serial 2-fold dilution from 10-fold to 5120-fold. Antibody titers that indicate a seroconversion
or 4-fold increase are in bold.
b The ELISA titer ratio is the highest ratio of acute-phase to convalescent-phase absorbance values at the same serum dilution tested. Significant increases
in antibody titers, indicated by ELISA titer ratios of 4, are in bold.
pressed recombinant nucleocapsid proteins were identified by
Western blot analysis as described elsewhere [8].
SARS-CoV–specific IgG was identified using a commercially
available indirect immunofluorescence assay (IFA) kit (Euroim-
mun) in accordance with the manufacturer’s instructions.HCoV-
229E– and HCoV-OC43–specific IgG was identified by an in-
house IFA, as described elsewhere [7], that was modified to use
HCoV-229E–infected MRC-5 cells and HCoV-OC43–infected
BSC-1 cells, respectively.
IgM and IgG antibodies to SARS-CoV were identified using
an ELISA test kit (Huada GBI Biotechnology) in accordance
with the manufacturer’s instructions. The nucleocapsid pro-
tein–based ELISA was performed as described elsewhere [6].
To ensure biosafety, experiments using serum samples from pa-
tients were performed in a biosafety level 2 laboratory.
One hundred serum samples were collected randomly from
healthy adult donors in October 2003. Serum samples were
collected from 34 patients with SARS 8–81 days after the onset
of symptoms. Paired serum samples were obtained from 11 of
these patients who exhibited seroconversion (table 1), from
whom the acute- and convalescent-phase serum samples were
collected on days 1–7 and days 12–159 after the onset of symp-
toms. SARS was diagnosed in accordance with the World Health
Organization’s criteria and was confirmed by assessment of se-
roconversion or a 4-fold increase in antibody titers against
SARS-CoV by IFA.
Results. The full lengths of 3 nucleocapsid genes from
HCoV-229E, HCoV-OC43, and SARS-CoV were amplified with
their corresponding primer pairs. The gene sizes were 1182,
1359, and 1281 bp for HCoV-229E, HCoV-OC43, and SARS-
CoV, respectively. The recombinant plasmids were sequenced,
and they were all in frame and had sequences matching those
of the nucleocapsid genes of the 3 CoVs. The expressed re-
combinant His6-tagged N-terminal nucleocapsid proteins were
identified by Western blot analysis using anti-His monoclonal
antibodies. The immunoreactive protein bands with expected
sizes are shown in figure 1A. The nucleocapsid proteins of
HCoV-229E, HCoV-OC43, and SARS-CoV reacted strongly and
specifically with the rabbit serum immune to the corresponding
nucleocapsid protein as immunoreactive protein bands on the
Western blot (figure 1B). No cross-reactivity was demonstrat-
ed among the nucleocapsid proteins of HCoV-229E, HCoV-
OC43, and SARS-CoV. These results indicate that no substan-
tial antigenic cross-reactivity occurred among the nucleocapsid
Figure 1. A, Western blot analysis of the expressed recombinant nucleocapsid proteins with anti-His monoclonal antibody. Each protein had a 6
histidine tag at the N-terminal end. Western blot results showed clear and specific bands at molecular weight (MW) positions 47, 44, and 50 kDa,
corresponding to the recombinant nucleocapsid proteins of severe acute respiratory syndrome (SARS)–associated coronavirus (CoV) (lane 1), human
CoV (HCoV)–229E (lane 2), and HCoV-OC43 (lane 3). B, Western blot analysis of the antigenicities of recombinant nucleocapsid proteins. Left, Nucleocapsid
protein of SARS-CoV with SARS-CoV–immune rabbit serum (lane 1), monoclonal antibody to the nucleocapsid protein of SARS-CoV (lane 2), HCoV-
229E–immune rabbit serum (lane 3), HCoV-OC43–immune rabbit serum (lane 4), and nonimmune rabbit serum (lane 5). Center, Nucleocapsid protein
of HCoV-229E with HCoV-229E–immune rabbit serum (lane 1), monoclonal antibody to the nucleocapsid protein of HCoV-229E (lane 2), SARS-CoV–
immune rabbit serum (lane 3), HCoV-OC43–immune rabbit serum (lane 4), and nonimmune rabbit serum (lane 5). Right, Nucleocapsid protein of HCoV-
OC43 with HCoV-OC43–immune rabbit serum (lane 1), monoclonal antibody to the nucleocapsid protein of HCoV-OC43 (lane 2), SARS-CoV–immune
rabbit serum (lane 3), HCoV-229E–immune rabbit serum (lane 4), and nonimmune rabbit serum (lane 5). All bands appear at the proper MW position.
C, Western blot analysis of the HCoV-229E culture filtrates with paired serum samples from patients with SARS (lanes 1–5), HCoV-229E–immune
rabbit serum (lane 6), HCoV-OC43–immune rabbit serum (lane 7), and monoclonal antibody to the nucleocapsid protein of HCoV-229E (lane 8). Lanes
4b (patient 4) and 5b (patient 7), which show results of convalescent-phase serum samples from 2 patients with SARS who had high titers in the
HCoV-229E nucleocapsid protein–based ELISA, exhibit prominent immunoreactive bands at ∼44 kDa. Reactions with specific monoclonal antibody to
the nucleocapsid protein of HCoV-229E are visible at the same MW. Three pairs of acute- and convalescent-phase serum samples had the same
reactive band at ∼44 kDa (lane 1, patient 10; lane 2, patient 8; lane 3, patient 3). All bands appear at the proper MW position.
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proteins of HCoV-229E, HCoV-OC43, and SARS-CoV when
immune rabbit serum was used.
SARS-CoV–immune rabbit serum reacted very strongly with
SARS-CoV–infected cells, moderately with HCoV-229E–infected
cells, and weakly with HCoV-OC43–infected cells by IFA. Con-
versely, HCoV-229E–immune rabbit serum reacted very strong-
ly with HCoV-229E–infected cells but did not react with either
SARS-CoV– or HCoV-OC43–infected cells. HCoV-OC43–im-
mune rabbit serum reacted very strongly with HCoV-OC43–in-
fected cells and strongly with HCoV-229E–infected cells but did
not react with SARS-CoV–infected cells. Furthermore, SARS-
CoV– and HCoV-OC43–immune rabbit serum showed weak
fluorescent signals from uninfected MRC-5 and BSC-1 cells,
compared with the response in nonimmune rabbit serum.
To determine the serological response to nucleocapsid proteins
of the 3 CoVs, 100 serum samples collected from healthy donors
and 34 serum samples collected from patients with SARS were
tested with recombinant nucleocapsid proteins of HCoV-229E,
HCoV-OC43, and SARS-CoV using a Western blot analysis. The
serum samples from healthy donors showed strong reactivity to
the nucleocapsid proteins of HCoV-229E and HCoV-OC43, with
positive results in 97% and 99% of the samples, respectively.
Only 2 samples (2%) reacted with the SARS-CoV nucleocapsid
protein. In contrast, the serum samples from patients with SARS
obtained 8–81 days after the onset of symptoms showed strong
immunoreactivity to the nucleocapsid proteins of HCoV-229E,
HCoV-OC43, and SARS-CoV, with positive results in 97%, 100%,
and 100% of the samples, respectively.
When CoV-infected cells were used, results were positive for
IgG antibodies by IFA in 98% (HCoV-229E), 100% (HCoV-
OC43), and 1% (SARS-CoV) of the serum samples from healthy
donors. Two samples from healthy donors had no antibody
response to HCoV-229E by IFA and no antibody response to
the nucleocapsid protein of HCoV-229E by Western blot analy-
sis. One sample collected in October 2003 had an antibody
response to SARS-CoV by IFA and to the nucleocapsid protein
of SARS-CoV by Western blot analysis. However, 100% of the
samples from 34 patients with SARS had antibody responses
to HCoV-229E, HCoV-OC43, and SARS-CoV. In healthy do-
nors, the results of the IFA showed the presence of antibodies
in response to the nucleocapsid proteins of HCoV-229E and
HCoV-OC43 in association with the presence of IgG antibodies
to both HCoVs, but antibodies to SARS-CoV were absent in
all samples except 1, which had a low antibody titer of 1:10,
compared with the usual antibody titer of at least 1:100 in most
patients with SARS. The serum samples from patients with
SARS had antibody responses to SARS-CoV as well as to HCoV-
229E and HCoV-OC43 when nucleocapsid proteins were used
in the Western blot analysis and when CoV–infected cells were
used in the IFA.
Paired serum samples from 11 patients with SARS were used
to determine antigenic relationships among the 3 CoVs by IFA
and ELISA. The antibody titers to HCoV-229E, HCoV-OC43,
and SARS-CoV are shown in table 1. To determine which viral
antigen was responsible for the cross-reactions, the culture fil-
trate from cells infected with HCoV-229E and HCoV-OC43
was immunoblotted with the paired serum samples. A strong
band at ∼44 kDa, the same molecular weight at which there
was a reaction with a specific monoclonal antibody to the nu-
cleocapsid protein of HCoV-229E, was observed in convales-
cent-phase samples from 2 patients with SARS (figure 1C).
These serum samples also displayed higher antibody titers in
the HCoV-229E nucleocapsid protein–based ELISA. The paired
serum samples from the 9 other patients also had a weak or
moderate reactive band at ∼44 kDa when they were immuno-
blotted with HCoV-229E. Acute-phase or convalescent-phase se-
rum from 11 paired serum samples had a weak reactive band
at ∼50 kDa, the same molecular weight at which there was a
reaction with a specific monoclonal antibody to the nucleo-
capsid protein of HCoV-OC43 when it was immunoblotted
with HCoV-OC43 (data not shown).
Discussion. Our results indicate that no nucleocapsid pro-
tein antigenic cross-reactivity was found between SARS-CoV and
rabbit serum immune to either HCoV-229E or HCoV-OC43.
In our previous studies, neither specific monoclonal nor poly-
clonal antibodies to the nucleocapsid protein of SARS-CoV cross-
reacted with HCoV-229E or HCoV-OC43 [8, 10]. However, a
previous study has described cross-reactivity between the nu-
cleocapsid proteins of SARS-CoV and those of group I CoVs [4].
This cross-reactivity may depend on the type of serum used.
Another investigator has demonstrated that HCoV-229E–im-
mune animal serum cross-reacted with SARS-CoV [1]. In the
present study, when we used immunofluorescent staining of
CoV-infected cells, HCoV-229E– and HCoV-OC43–immune
rabbit serum did not cross-react with SARS-CoV–infected cells,
whereas SARS-CoV–immune rabbit serum had moderate cross-
reactivity with HCoV-229E–infected cells and weak cross-re-
activity with HCoV-OC43–infected cells. Although SARS-CoV–
immune rabbit serum that had high antibody titers for SARS-
CoV was slightly contaminated with antibodies to host cell
components, it is apparent that the serum had cross-reactiv-
ity with HCoV-229E and HCoV-OC43. In addition, the IFA
showed that HCoV-OC43–immune rabbit serum had strong
cross-reactivity with HCoV-229E. This cross-reactivity has been
observed by some investigators [11, 12] but not by others [13,
14]. It is possible that some antibodies in the rabbit serum
reacted against the host cells or cross-reacted with HCoV-229E.
Because the 2 known HCoVs are responsible for ∼30% of
all common colds [2], it is not unexpected that 97% and 99%
of serum samples from healthy donors had antibodies to HCoV-
229E and HCoV-OC43, respectively. Therefore, it is expected
that the antibodies to HCoV-229E and HCoV-OC43 found in
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the serum samples from patients with SARS either preexisted
or were cross-reacting antibodies to HCoV-229E and HCoV-
OC43. Further studies of this issue are warranted. The IFA
showed that paired serum samples exhibited a4-fold increase
in antibody titers against HCoV-229E and HCoV-OC43 in 5
of 11 and 10 of 11 patients with SARS, respectively. Such a
high antibody titer response to the known HCoVs in patients
with SARS may represent an anamnestic reaction to previous
infections with the 2 known HCoVs or other CoVs or a cross-
reaction between SARS-CoV and HCoV-229E or HCoV-OC43.
However, the nucleocapsid protein–based ELISA detected in-
creases in antibody titers in only 2 of 11 paired serum samples
from patients with SARS when the nucleocapsid protein of
HCoV-229E was used as an antigen, and they had a consistently
increased signal reaction to the nucleocapsid protein from
HCoV-229E–infected cell culture filtrate by Western blot analy-
sis (figure 1C). Paired serum samples from patients with SARS
showed no consistent increase in antibody titers in the HCoV-
OC43 nucleocapsid protein–based ELISA and no increase in
signal reaction to the nucleocapsid protein from HCoV-OC43–
infected cell culture filtrate by Western blot analysis. These
results confirm the suggestion that the major antigenic cross-
reactivity with HCoV-OC43 in the convalescent-phase serum
samples of patients with SARS is due not to nucleocapsid pro-
teins but to other viral components. Although the paired serum
samples from patients with SARS showed a partial cross-re-
action to HCoV-229E, there was no significant close correlation
between the IFA titer ratios, which were determined in response
to whole virus–infected cells, and the ELISA titer ratios, which
were determined in response to nucleocapsid proteins. Fur-
thermore, antibodies to SARS-CoV could be detected in only
1 serum sample from a healthy donor by either IFA or nu-
cleocapsid protein–based Western blot analysis, even though
patients with SARS had antibodies to HCoV-229E and HCoV-
OC43. Therefore, there is no serological cross-reactivity with
SARS-CoV in healthy donors even though they have a high
reactivity to HCoVs [15].
In summary, SARS-CoV had apparent antigenic 1-way cross-
reactivity to the 2 known HCoVs. Although it is not clear which
antigenic determinants were involved, the overall results suggest
that SARS-CoV and HCoV-OC43 are more closely antigenically
related than are SARS-CoV and HCoV-229E. Studies using a
number of purified recombinant viral components from CoVs
as antigens to identify the antibodies produced during infection
and to determine the antigenic relationships among CoVs are
in progress.
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